Valneva (NASDAQ:VALN) Shares Gap Down – Time to Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $5.95, but opened at $5.60. Valneva shares last traded at $5.60, with a volume of 5,504 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Guggenheim set a $11.00 target price on shares of Valneva in a research report on Thursday, April 16th. Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday. Finally, The Goldman Sachs Group downgraded shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price for the company. in a research note on Wednesday, April 22nd. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $11.98.

Valneva Price Performance

The company’s fifty day moving average is $5.90 and its 200 day moving average is $8.28. The firm has a market cap of $538.03 million, a price-to-earnings ratio of -3.03 and a beta of 1.75. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14.

Valneva (NASDAQ:VALN) last announced its earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.The business had revenue of $35.77 million for the quarter. On average, equities research analysts predict that Valneva SE Sponsored ADR will post -1 EPS for the current year.

Institutional Trading of Valneva

A number of large investors have recently added to or reduced their stakes in VALN. Marex Group plc acquired a new stake in Valneva in the second quarter valued at $64,000. XTX Topco Ltd acquired a new stake in Valneva in the 4th quarter worth about $94,000. JPMorgan Chase & Co. bought a new position in Valneva in the 3rd quarter valued at about $124,000. China Universal Asset Management Co. Ltd. bought a new position in Valneva in the 4th quarter valued at about $44,000. Finally, VSM Wealth Advisory LLC increased its position in Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.